

ZONAGEN INC  
Form 8-K  
March 08, 2005

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**Current Report Filed Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

**Date of Report  
(Date of earliest event reported): March 7, 2005**

**Zonagen, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware  
(State or other jurisdiction of  
incorporation or organization)**

**0-21198  
(Commission File Number)**

**76-0233274  
(I.R.S. Employer Identification  
No.)**

**2408 Timberloch Place, Suite B-1  
The Woodlands, Texas 77380  
(Address of principal  
executive offices  
and zip code)  
(281) 719-3400  
(Registrant's telephone  
number, including area code)**

---

**TABLE OF CONTENTS**

Item 8.01. Other Information

Item 9.01. Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

Press Release dated March 7, 2005

---

**Table of Contents**

**Item 8.01. Other Information**

Zonagen, Inc. announced in a press release on March 7, 2005 that, on February 23, 2005, the United States Patent and Trademark Office (the "USPTO") issued a second and final rejection of all claims in the reexamination proceedings of U.S. Pat. No. 6,391,920 (the "920 patent"), which is related to a method of treating testosterone deficiency in men using an anti-estrogen such as clomiphene.

A copy of the Company's press release is attached hereto as Exhibit 99.1. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

**Item 9.01. Financial Statements and Exhibits**

c. Exhibits

| Exhibit<br>Number | Description                        |
|-------------------|------------------------------------|
| 99.1              | Press Release dated March 7, 2005. |

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Zonagen, Inc.**

Date: March 8, 2005.

By: /s/ Louis Ploth, Jr.  
Louis Ploth, Jr.  
Vice President, Business Development  
and  
Chief Financial Officer

---

**Table of Contents**

**EXHIBIT INDEX**

| Exhibit<br>Number | Description                        |
|-------------------|------------------------------------|
| 99.1              | Press Release dated March 7, 2005. |